SLN logo

Silence Therapeutics (SLN) Company Overview

Profile

Full Name:

Silence Therapeutics plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

September 8, 2020

Indexes:

Not included

Website:

http://www.silence-therapeutics.com

Description:

Silence Therapeutics is a biotechnology company focused on developing innovative RNA-based therapies. They use their proprietary technology to create treatments for serious diseases, including cancer and genetic disorders. Their goal is to harness the power of RNA to improve patient outcomes and advance medicine.

Key Details

Price

$4.78

Market Cap

$225.69 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$31.57 M(+45.69% YoY)

Annual EPS

-$1.45(+6.71% YoY)

PE Ratio

-

Annual ROE

-222.33%

Annual Debt To Equity

0.00

Beta

1.32

Events Calendar

Earnings

Next earnings date:

May 16, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 5, 25 Morgan Stanley
Overweight
Mar 4, 25 Goldman Sachs
Sell
Mar 4, 25 BMO Capital
Outperform
Feb 11, 25 Goldman Sachs
Sell
Feb 3, 25 HC Wainwright & Co.
Buy
Jan 29, 25 HC Wainwright & Co.
Buy
Dec 10, 24 Chardan Capital
Buy
Dec 9, 24 HC Wainwright & Co.
Buy
Nov 20, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy

Screeners with SLN included

Growing Shares Outstanding
Stocks with high beta
UK stocks
Stocks below SMA 200
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$4.78
SLN price is $4.78

Price All-time High

$28.35
SLN price is currently -83.14% below its historical high of $28.35

Price Analysts Target

-
SLN price consensus analysts' forecast is unknown

Price Most Recent Change

+7.17%
SLN price was up +7.17% on Mar 5, 2025

Price YTD Change

-31.62%
SLN price is down -31.62% since January 1st

Price 3-Year Change

-71.93%
SLN price is down -71.93% over the past 3 years

Market cap

Market Cap

$225.69 M
SLN market capitalization is $225.69 million

Market Cap 3-Year Change

-55.72%
SLN market capitalization is down -55.72% over the past 3 years

Market Cap All-time High

$1.25 B
SLN market capitalization is currently -81.93% below its historical high of $1.25 billion

Market Cap Sector Rank

57.2%
SLN market capitalization is higher than 57.2% of companies in Healthcare sector

Technical

Beta

1.32
SLN beta is 1.32

200-day SMA

$14.31
SLN price is currently -66.60% below its 200-day simple moving average

14-day RSI

44.47
SLN 14-day relative strength index is 44.47

30-day Relative Volume

0.53
SLN 30-day relative volume is 0.53

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$31.57 M
SLN annual revenue is $31.57 million

Annual Revenue Analysts Estimate

$19.81 M
SLN annual revenue is currently +59.42% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

+45.69%
SLN annual revenue is up +45.69% year-on-year

Annual Revenue Sector Rank

42.04%
SLN annual revenue is higher than 42.04% of companies in Healthcare sector

Profit

Annual Gross Profit

$18.74 M
SLN annual gross profit is $18.74 million

Annual Gross Margin

59.34%
SLN annual gross profit margin is 59.34%

Annual Operating Profit

-$61.72 M
SLN annual operating income is -$61.72 million

Annual Operating Margin

-195.48%
SLN annual operating profit margin is -195.48%

Annual Net Income

-$53.84 M
SLN annual net profit is -$53.84 million

Annual Net Margin

-170.51%
SLN annual net profit margin is -170.51%

EPS

Annual EPS

-$1.45
SLN annual earnings per share is -$1.45

Annual EPS Analysts Estimate

-$0.85
SLN annual earnings per share is currently +71.08% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+6.71%
SLN annual earnings per share is up +6.71% year-on-year

Annual EPS Sector Rank

50%
SLN annual earnings per share is higher than 50% of companies in Healthcare sector

ROA & ROE

Annual ROA

-43.14%
SLN annual return on assets is -43.14%

Annual ROE

-222.33%
SLN annual return on equity is -222.33%

EBIT & EBITDA

Annual EBIT

-$62.56 M
SLN annual earnings before interest & taxes is -$62.56 million

Annual EBITDA

-$61.94 M
SLN annual EBITDA is -$61.94 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
SLN price to earnings ratio value is unknown

PE Ratio Sector Rank

-
SLN price to earnings ratio is unknown

PB Ratio

PB Ratio

1.78
SLN price to book ratio is 1.78

PB Ratio Sector Rank

56.35%
SLN price to book ratio is higher than 56.35% of companies in Healthcare sector

PS Ratio

PS Ratio

10.96
SLN price to sales ratio is 10.96

PS Ratio Sector Rank

78.44%
SLN price to sales ratio is higher than 78.44% of companies in Healthcare sector

Enterprise value

Enterprise Value

$142.97 M
SLN enterprise value is $142.97 million

Enterprise Value Sector Rank

52.22%
SLN enterprise value is higher than 52.22% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.98
SLN EV/EBITDA is -1.98

EV/EBITDA Sector Rank

35.99%
SLN EV/EBITDA is higher than 35.99% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.56
SLN annual current ratio is 4.56

Annual Quick Ratio

-
SLN annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
SLN annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-1478.95
SLN annual interest coverage ratio is -1478.95

Risk & Stability

Piotroski F-Score

3
SLN piotroski f-score is 3

Altman Z-Score

-3.81
SLN altman z-score is -3.81

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$119.52 M
SLN annual total assets is $119.52 million

Annual Non Current Assets

$16.31 M
SLN annual long term assets is $16.31 million

Annual Current Assets

$103.21 M
SLN annual total current assets is $103.21 million

Annual Cash & Cash Equivalents

$68.83 M
SLN annual cash & cash equivalents is $68.83 million

Equity

Annual Book Value

$21.72 M
SLN annual book value is $21.72 million

Annual Working Capital

$80.58 M
SLN annual working capital is $80.58 million

Liabilities

Annual Total Liabilities

$97.80 M
SLN annual total liabilities is $97.80 million

Annual Total Long Term Liabilities

$75.16 M
SLN annual total long term liabilities is $75.16 million

Annual Current Liabilities

$22.64 M
SLN annual total current liabilities is $22.64 million

Annual Accounts Payable

$3.35 M
SLN annual accounts payable is $3.35 million

Debt

Annual Total Debt

$346.50 K
SLN annual total debt is $346.50 thousand

Annual Total Debt 1-Year Change

-35.8%
SLN annual total debt is down -35.8% year-on-year

Annual Long Term Debt

$118.50 K
SLN annual long term debt is $118.50 thousand

Annual Short Term Debt

$228.00 K
SLN annual short term debt is $228.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$93.30 M
SLN annual total expenses is $93.30 million

Annual Operating Expenses

$80.46 M
SLN annual total operating expenses is $80.46 million

Annual Cost Of Goods Sold

$12.84 M
SLN annual cost of goods sold is $12.84 million

Annual SGA

$25.68 M
SLN annual SGA is $25.68 million

Annual D&A

$619.70 K
SLN annual depreciation & amortization is $619.70 thousand

Annual Interest Expense

$42.30 K
SLN annual interest expense is $42.30 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$48.96 M
SLN annual cash flow from operations is -$48.96 million

Annual CFO 1-Year Change

+13.01%
SLN annual cash flow from operations is up +13.01% year-on-year

Annual CFI

$20.44 M
SLN annual cash flow from investing activities is $20.44 million

Annual CFI 1-Year Change

+199.8%
SLN annual cash flow from investing activities is up +199.8% year-on-year

Annual CFF

$31.30 M
SLN annual cash flow from financing activities is $31.30 million

Annual CFF 1-Year Change

-41.28%
SLN annual cash flow from financing activities is down -41.28% year-on-year

Free CashFlow

Annual FCF

-$49.02 M
SLN annual free cash flow is -$49.02 million

Annual FCF 1-Year Change

+13.75%
SLN annual free cash flow is up +13.75% year-on-year

CAPEX

Annual CAPEX

$56.00 K
SLN annual capital expenditures is $56.00 thousand

Annual CAPEX 1-Year Change

-89.72%
SLN annual capital expenditures is down -89.72% year-on-year

Institutional Ownership

Similar stocks

VYGR logo
Voyager Therapeutics (VYGR)
RCEL logo
AVITA Medical (RCEL)
CDXS logo
Codexis (CDXS)
TNGX logo
Tango Therapeutics (TNGX)
ABEO logo
Abeona Therapeutics (ABEO)
ELMD logo
Electromed (ELMD)
Neumora Therapeutics (NMRA)
ZYXI logo
Zynex (ZYXI)
AMLX logo
Amylyx Pharmaceuticals (AMLX)

FAQ

  • What is the ticker symbol for Silence Therapeutics?
  • Does Silence Therapeutics pay dividends?
  • What sector is Silence Therapeutics in?
  • What industry is Silence Therapeutics in?
  • What country is Silence Therapeutics based in?
  • When did Silence Therapeutics go public?
  • Is Silence Therapeutics in the S&P 500?
  • Is Silence Therapeutics in the NASDAQ 100?
  • Is Silence Therapeutics in the Dow Jones?
  • When was Silence Therapeutics's last earnings report?
  • When does Silence Therapeutics report earnings?

What is the ticker symbol for Silence Therapeutics?

The ticker symbol for Silence Therapeutics is NASDAQ:SLN

Does Silence Therapeutics pay dividends?

No, Silence Therapeutics does not pay dividends

What sector is Silence Therapeutics in?

Silence Therapeutics is in the Healthcare sector

What industry is Silence Therapeutics in?

Silence Therapeutics is in the Biotechnology industry

What country is Silence Therapeutics based in?

Silence Therapeutics is headquartered in United Kingdom

When did Silence Therapeutics go public?

Silence Therapeutics's initial public offering (IPO) was on September 8, 2020

Is Silence Therapeutics in the S&P 500?

No, Silence Therapeutics is not included in the S&P 500 index

Is Silence Therapeutics in the NASDAQ 100?

No, Silence Therapeutics is not included in the NASDAQ 100 index

Is Silence Therapeutics in the Dow Jones?

No, Silence Therapeutics is not included in the Dow Jones index

When was Silence Therapeutics's last earnings report?

Silence Therapeutics's most recent earnings report was on Feb 27, 2025

When does Silence Therapeutics report earnings?

The next expected earnings date for Silence Therapeutics is May 16, 2025